And given the current clinical framework for prostate cancer, where raising prostate-specific antigen (PSA) is commonly used as a biochemical surrogate of clinical recurrence, and tissue biopsies are not routinely collected, repurposing of an already approved drug like ITZ, which can potentiate DTX chemotherapy, and overcome ABCB1-mediated drug resistance without adding severe toxicity may be a viable strategy. Here, ABCB1 is linked to prostate cancer.